Brandi Hayes, MS, OTR/L in Combs, KY - Occupational Therapist

Brandi Hayes, MS, OTR/L is a Occupational Therapist based in Combs, Kentucky. Brandi Hayes is licensed to practice in Kentucky (license number 165220) and her current practice location is 104 Bailey St, Combs, Kentucky. She can be reached at her office (for appointments etc.) via phone at (606) 260-3153.

NPI number for Brandi Hayes is 1891226866 and her current mailing address is Po Box 75, Combs, Kentucky. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1891226866.

Contact Information

	Brandi Hayes, MS, OTR/L
	104 Bailey St, Combs, KY 41729
	(606) 260-3153
	Not Available

Healthcare Provider's Profile

Full Name	Brandi Hayes
Gender	Female
Speciality	Occupational Therapist
Location	104 Bailey St, Combs, Kentucky
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1891226866
Provider Enumeration Date: 03/22/2017
Last Update Date: 03/22/2017

Medical Identifiers

Medical identifiers for Brandi Hayes such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1891226866	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
225X00000X	Occupational Therapist	165220 (Kentucky)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Brandi Hayes is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Brandi Hayes, MS, OTR/L Po Box 75, Combs, KY 41729-0075 Ph: (606) 260-3153	Brandi Hayes, MS, OTR/L 104 Bailey St, Combs, KY 41729 Ph: (606) 260-3153

News Archive

Medarex announces preliminary data for investigational anti-PD-1 antibody

Medarex, Inc. has announced preliminary data from an ongoing Phase 1 study of MDX-1106 (ONO-4538: development code of Ono Pharmaceutical Co., Ltd.), a fully human anti-PD-1 antibody.

Assessing physician compliance with the rules for euthanasia and assisted suicide

Physicians in the Netherlands rely on careful patient evaluations and official practice guidelines when considering patient requests for euthanasia and physician-assisted suicide (EAS), according to a study in the August 8/22 issue of Archives of Internal Medicine.

Merck KGaA, Darmstadt, Germany announces CE Mark certification for two innovative fertility technologies

Merck KGaA, Darmstadt, Germany, a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials, today announced that the two innovative fertility technologies Gavi and Geri have cleared a major milestone, achieving CE Mark certification.

Medtronic announces results from two Symplicity system trials on treatment-resistant hypertension

Medtronic, Inc., announced that the Symplicity renal denervation system provides safe, significant and sustained blood pressure reduction up to three years in patients with treatment-resistant hypertension, according to data from two clinical trials presented at the 2012 American College of Cardiology (ACC) meeting.

Brandi Hayes, MS, OTR/L - Occupational Therapist in Combs, KY